44TH GENERAL SESSION OF THE EUFMD COMMISSION
ONLINE 21-22-23 APRIL 2021
Overview of activities conducted by the EU reference laboratory Presenter: Labib Bakkali Kassimi, ANSES on behalf of the EURL for FMD (Appendix 2)
Key Messages 1. The new EURL was appointed on the 1st of January 2019 as a consortium between Anses and Sciensano. 2. The EURL provides technical assistance to MS and works to improve and maintain diagnostic capacity through organisation of annual proficiency test (PT) and sharing relevant information on FMD with the network during its annual workshop. PT 2021 is ongoing, with a face-to-face workshop currently planned for November 2021 3. The EURL contributes to the global monitoring and control of FMD through collaboration with OIE, FAO and EuFMD by providing diagnostic services, training and expertise missions. 4. Survey on the needs and perspectives for the EU Reference laboratory network was conducted. The Covid-19 pandemic has highlighted the need to set up a bank of FMD diagnostic reagents and kits at national and/or European level. Collaborative research project proposal on assessment of efficacy of A vaccines against A/Africa/GIV was submitted to the Standing Technical Committee (STC).
Summary The new EURL was appointed on the 1st January 2019 as a consortium between ANSES in France and Sciensano in Belgium. The EURL has set up a website (http://eurl-fmd.anses.fr) to share information with its network of 40 European laboratories. The EURL organizes an annual proficiency test (PT) based on outbreak scenarios to improve and maintain diagnostic capacity of the European laboratories. In 2019 and 2020, 38 countries participated in the PT including 31 countries supported by the EURL and seven countries supported by the EuFMD via a Letter of Agreement signed with ANSES. For the 2021 PT, 40 laboratories from 38 countries registered for participation. The panels will be shipped to participants by the end of May. The EURL organized its first annual scientific workshop in October 2019 at ANSES in France. Fifty-six participants from 35 countries attended the meeting. Due to the Covid-19 pandemic, the 2020 workshop was organized on line and this allowed more participants (70) to attend the meeting. However, although participants evaluated the WS as excellent or very good, they expressed the need of face-to-face meeting that would improve communication and allow having more presentations. During the workshop, outcomes of a survey conducted by EURL on the needs and perspectives for the EU Reference laboratory network were presented and discussed. Participants have expressed interest in setting up a national bank (73%) and/or EU bank (85.8%) of FMD diagnostic reagents and kits. The efficacy of available A vaccines against A/Africa/G-IV strains was also discussed given the poor in-vitro vaccine-matching data performed by the WRL for recent virus strains from Egypt and East Africa and the lack of in-vivo vaccine protection data. In order to clarify this issue, a collaborative research project proposal on assessment of vaccines against A/Africa/G-IV was submitted to the Standing Technical Committee (STC), to perform additional in-vitro vaccine matching and to carry out an in-vivo vaccine protection study. 14
